AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10746444 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium, 0.1% eyedrops, 1 drop, 4 times a day for 28 days
Number of subjects: 32
Study 10746444 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride, 5% drops, 1 drop, 4 times a day for 28 days
Number of subjects: 32
Study 9362654 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered smoking cessation intervention
Number of subjects: 0
Study 1535082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (21, 42, 84, and 168 micrograms)
Number of subjects: 20
Study 1535082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1535082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (168 micrograms)
Number of subjects: 20
Study 3915282 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP
Number of subjects: 41
Study 3915282 — intervention group
Group type: EXPERIMENTAL
Intervention: DDR
Number of subjects: 41
Study 30352580 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory development and implementation of a community-based program to promote outdoor physical activity
Number of subjects: 8
Study 30352580 — intervention group
Group type: COMPARATOR
Intervention: No intervention (controls)
Number of subjects: 8
Study 27220960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib plus Erlotinib (400 mg twice daily plus 150 mg once daily)
Number of subjects: 720
Study 27220960 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib plus Placebo (400 mg twice daily plus placebo)
Number of subjects: 720
Study 25509708 — intervention group
Group type: EXPERIMENTAL
Intervention: Open group discussion
Number of subjects: 73
Study 25509708 — intervention group
Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 73
Study 22524549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 0
Study 22524549 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI) therapy
Number of subjects: 0
Study 19937133 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted chemiluminescent membrane array (WCHMA) method
Number of subjects: 0
Study 19937133 — intervention group
Group type: COMPARATOR
Intervention: Previously designed membrane array method
Number of subjects: 0
Study 18219530 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprayable hydrogel adhesion barrier (SprayGel)
Number of subjects: 40
Study 18219530 — intervention group
Group type: COMPARATOR
Intervention: Control (no adhesion barrier)
Number of subjects: 40
Study 15711353 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant GNRH therapy (1.2 mg per day as nasal spray for 4 weeks)
Number of subjects: 42
Study 15711353 — intervention group
Group type: COMPARATOR
Intervention: Orchiopexy alone
Number of subjects: 42
Study 14658952 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone treatment (0.02‐0.06 mg/kg/day)
Number of subjects: 700
Study 10781483 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 microg. kg(‐1) of ephedrine
Number of subjects: 60
Study 10781483 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg. kg(‐1) esmolol
Number of subjects: 60
Study 10781483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8765249 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle colposuspension
Number of subjects: 32
Study 8765249 — intervention group
Group type: COMPARATOR
Intervention: Bladder neck endopelvic fascia plication
Number of subjects: 32
Study 1484945 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 19
Study 1484945 — intervention group
Group type: COMPARATOR
Intervention: High fat diet
Number of subjects: 19
Study 6424926 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC plus oral administration of Futraful for 3 months (protocol II, group B)
Number of subjects: 1805
Study 6424926 — intervention group
Group type: COMPARATOR
Intervention: Intermittent intravenous injection of a moderate dose of MMC (protocol I, group A)
Number of subjects: 1805
Study 6424926 — intervention group
Group type: COMPARATOR
Intervention: Bolus intravenous injection of MMC (protocol II, group A)
Number of subjects: 1805
Study 29209917 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment
Number of subjects: 860
Study 28341959 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP 980
Number of subjects: 157
Study 28341959 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab (US)
Number of subjects: 157
Study 28341959 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab (EU)
Number of subjects: 157
Study 25797522 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells (BMMCs)
Number of subjects: 36
Study 25797522 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 36
Study 23279074 — intervention group
Group type: EXPERIMENTAL
Intervention: High DHA (∼1%)
Number of subjects: 657
Study 23279074 — intervention group
Group type: COMPARATOR
Intervention: Standard DHA (∼0.3%)
Number of subjects: 657
Study 23279074 — intervention group
Group type: EXPERIMENTAL
Intervention: High DHA (∼1%) in boys
Number of subjects: 657
Study 23279074 — intervention group
Group type: COMPARATOR
Intervention: Standard DHA (∼0.3%) in boys
Number of subjects: 657
Study 21216077 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam + low-dose ketamine (0.03 mg/kg midazolam + 0.3 mg/kg ketamine + saline)
Number of subjects: 50
Study 21216077 — intervention group
Group type: COMPARATOR
Intervention: Midazolam + placebo (0.03 mg/kg midazolam + 2 mL placebo)
Number of subjects: 50
Study 18474731 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesofensine 0.5 mg
Number of subjects: 0
Study 18474731 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesofensine 0.25 mg
Number of subjects: 0
Study 18474731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16311076 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring using an instrumented paper-and-pencil diary (invivodata, inc.)
Number of subjects: 0
Study 16311076 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring (electronically recorded)
Number of subjects: 0
Study 14551237 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/d pravastatin
Number of subjects: 27
Study 10960382 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPP
Number of subjects: 20
Study 10960382 — intervention group
Group type: COMPARATOR
Intervention: TEP
Number of subjects: 20
Study 8618094 — intervention group
Group type: EXPERIMENTAL
Intervention: Excalibur handpiece
Number of subjects: 24
Study 8618094 — intervention group
Group type: COMPARATOR
Intervention: Manual hand instrumentation (K-files)
Number of subjects: 24
Study 1599062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.2 mg
Number of subjects: 37
Study 1599062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.1 mg
Number of subjects: 37
Study 1599062 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 6399698 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant razoxane treatment (61 patients)
Number of subjects: 126
Study 6399698 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (65 patients)
Number of subjects: 126
Study 30939778 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy activities (two different types) added to standard care for 25 weekly sessions
Number of subjects: 90
Study 29112488 — intervention group
Group type: EXPERIMENTAL
Intervention: RIBSP vaccine
Number of subjects: 150
Study 29112488 — intervention group
Group type: COMPARATOR
Intervention: VAXIGRIP® vaccine
Number of subjects: 150
Study 27151222 — intervention group
Group type: EXPERIMENTAL
Intervention: Romega® 30 (phospholipid-rich herring roe oil)
Number of subjects: 32
Study 27151222 — intervention group
Group type: COMPARATOR
Intervention: TAG-rich fish oil
Number of subjects: 32
Study 25188403 — intervention group
Group type: EXPERIMENTAL
Intervention: Active education group (one‐on‐one technique coaching)
Number of subjects: 123
Study 25188403 — intervention group
Group type: COMPARATOR
Intervention: Passive group (device‐specific instruction pamphlet only)
Number of subjects: 123
Study 21842998 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical representations (high iconicity)
Number of subjects: 275
Study 21842998 — intervention group
Group type: COMPARATOR
Intervention: Numerical representations (low iconicity)
Number of subjects: 275
Study 21842998 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical representations
Number of subjects: 275
Study 21842998 — intervention group
Group type: COMPARATOR
Intervention: Numerical representations
Number of subjects: 275
Study 19678756 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP level > or =5 microg/mL at baseline
Number of subjects: 273
Study 19678756 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 level > or =3 pg/mL at baseline
Number of subjects: 273
Study 19678756 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP level > or =5 microg/mL (latest follow-up)
Number of subjects: 273
Study 19678756 — intervention group
Group type: EXPERIMENTAL
Intervention: amyloid-A level > or =6 mg/L (latest follow-up)
Number of subjects: 273
Study 19678756 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 level > or =3 pg/mL (latest follow-up)
Number of subjects: 273
Study 17195936 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 383
Study 17195936 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A or B vaccines (Control)
Number of subjects: 383
Study 15504991 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 139
Study 15504991 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDII)
Number of subjects: 139
Study 11216970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent transdermal nitroglycerin (NTG) 0.6 mg/h
Number of subjects: 20
Study 11216970 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 20
Study 9850367 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms b.i.d.
Number of subjects: 482
Study 9850367 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 micrograms b.i.d.
Number of subjects: 482
Study 8737894 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower energy high-fat, low-CHO meal (3181 kJ, fat:CHO energy ratio 54:41)
Number of subjects: 18
Study 8737894 — intervention group
Group type: COMPARATOR
Intervention: Higher energy low-fat, high-CHO meal (3599 kJ, fat:CHO energy ratio 7:88)
Number of subjects: 18
Study 2201706 — intervention group
Group type: EXPERIMENTAL
Intervention: TTC‐WP
Number of subjects: 9
Study 2201706 — intervention group
Group type: COMPARATOR
Intervention: WP only
Number of subjects: 9
Study 2201706 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing
Number of subjects: 9
Study 2201706 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 9
Study 6777073 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA, 1.5 g/day)
Number of subjects: 946
Study 6777073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 946
Study 6777073 — intervention group
Group type: COMPARATOR
Intervention: Phenprocoumon
Number of subjects: 946
Study 30380956 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique intradermal suture (OIS)
Number of subjects: 120
Study 30380956 — intervention group
Group type: COMPARATOR
Intervention: Conventional interrupted intradermal suture (IS)
Number of subjects: 120
Study 27075895 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visit program (VG)
Number of subjects: 360
Study 27075895 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 360
Study 23246016 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric iodine-uptake (VIU) measurement
Number of subjects: 15
Study 23246016 — intervention group
Group type: EXPERIMENTAL
Intervention: Choi criteria
Number of subjects: 15
Study 23246016 — intervention group
Group type: COMPARATOR
Intervention: AASLD criteria
Number of subjects: 15
Study 19501433 — intervention group
Group type: EXPERIMENTAL
Intervention: PainMatcher (PM)
Number of subjects: 57
Study 19501433 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 57
Study 19390223 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment after 6 weeks
Number of subjects: 0
Study 19390223 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission plasma tryptophan concentrations
Number of subjects: 0
Study 19390223 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment plasma tryptophan concentrations
Number of subjects: 0
Study 19390223 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment kynurenine concentrations
Number of subjects: 0
Study 16713808 — intervention group
Group type: EXPERIMENTAL
Intervention: bovine organic osseous matrix (BOM) and bovine bone morphogenetic protein (bBMP)
Number of subjects: 10
Study 16713808 — intervention group
Group type: COMPARATOR
Intervention: autogenous bone graft from mandibular ramus
Number of subjects: 10
Study 14766455 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine follow-up in secondary care
Number of subjects: 0
Study 14766455 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal questionnaire
Number of subjects: 0
Study 11288371 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular questioning style
Number of subjects: 28
Study 11288371 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexive questioning style
Number of subjects: 28
Study 11288371 — intervention group
Group type: COMPARATOR
Intervention: Strategic questioning style
Number of subjects: 28
Study 11288371 — intervention group
Group type: COMPARATOR
Intervention: Lineal questioning style
Number of subjects: 28
Study 9054789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clomipramine
Number of subjects: 15
Study 9054789 — intervention group
Group type: COMPARATOR
Intervention: Oral clomipramine
Number of subjects: 15
Study 9054789 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clomipramine after intravenous loading
Number of subjects: 15
Study 8477180 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 micrograms)
Number of subjects: 20
Study 8477180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (200 micrograms)
Number of subjects: 20
Study 8477180 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oxitropium and fenoterol
Number of subjects: 20
Study 3080920 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition with antiphlebitic mixture (1000 IU heparin, 5 mg hydrocortisone, and 1.8 mEq sodium hydroxide as a buffer)
Number of subjects: 54
Study 3080920 — intervention group
Group type: COMPARATOR
Intervention: Peripheral parenteral nutrition without antiphlebitic mixture
Number of subjects: 54
Study 30910355 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance measurement between root apices and mandibular canal (MC)
Number of subjects: 1000
Study 30910355 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of distances based on gender
Number of subjects: 1000
Study 30910355 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact or invasion of roots with MC
Number of subjects: 1000
Study 30910355 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity of root apices to MC
Number of subjects: 1000
Study 30910355 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone density measurement
Number of subjects: 1000
Study 29921161 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at PC6
Number of subjects: 48
Study 29921161 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at PC7
Number of subjects: 48
Study 29921161 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at GB37
Number of subjects: 48
Study 29921161 — intervention group
Group type: COMPARATOR
Intervention: Disgust-induced (DI) stimuli only
Number of subjects: 48
Study 26715587 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnered strength training (Exercising Together)
Number of subjects: 64
Study 26715587 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 64
Study 24934276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis‐acting eSNPs
Number of subjects: 1205
Study 24934276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis‐acting eSNPs in FADS2
Number of subjects: 1205
Study 24934276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis‐acting eSNPs in NAGA
Number of subjects: 1205
Study 24934276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis‐acting eSNPs in F13A1
Number of subjects: 1205
Study 22656405 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-Ketamine combination
Number of subjects: 60
Study 22656405 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine-Midazolam combination
Number of subjects: 60
Study 20399997 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated flurbiprofen 100-mg tablet (test)
Number of subjects: 21
Study 20399997 — intervention group
Group type: COMPARATOR
Intervention: Film-coated immediate-release flurbiprofen 100-mg tablet (reference)
Number of subjects: 21
Study 18806023 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative low-dose ketamine (bolus dose of 0.5 mg/kg followed by continuous infusion of 4 microg.kg(‐1).min(‐1))
Number of subjects: 34
Study 18806023 — intervention group
Group type: COMPARATOR
Intervention: Saline (equal volume to ketamine)
Number of subjects: 34
Study 18806023 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative low-dose ketamine
Number of subjects: 34
Study 18806023 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 34
Study 15668289 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMV/MVAC (cisplatin, ifosphamide, methotrexate, vinblastine / methotrexate, vinblastine, doxorubicin, cisplatin)
Number of subjects: 116
Study 15668289 — intervention group
Group type: EXPERIMENTAL
Intervention: DC (docetaxel, cisplatin)
Number of subjects: 116
Study 15668289 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG performance status and haemoglobin levels
Number of subjects: 116
Study 11807146 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 837
Study 11807146 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B
Number of subjects: 837
Study 10084101 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion, 30 mg kg‐1 h‐1
Number of subjects: 42
Study 10084101 — intervention group
Group type: COMPARATOR
Intervention: Propofol infusion, 30 mg kg‐1 h‐1 + fentanyl bolus, 2 micrograms kg‐1 i.v.
Number of subjects: 42
Study 7560599 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (7 g three times daily for 3 days)
Number of subjects: 12
Study 7560599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1958973 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged fistulotomy (n = 24)
Number of subjects: 74
Study 1958973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting seton (n = 13)
Number of subjects: 74
Study 1958973 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term seton drainage (n = 14)
Number of subjects: 74
Study 1958973 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term seton drainage in patients with Crohn's disease (n = 23)
Number of subjects: 74
Study 7201089 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose bromocriptine therapy (average dose, 15 mg per day)
Number of subjects: 25
Study 7201089 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose bromocriptine therapy (initial dose 1 mg per day with slow escalation)
Number of subjects: 25
Study 7201089 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose bromocriptine therapy
Number of subjects: 25
Study 29889581 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoothie 1
Number of subjects: 10
Study 29889581 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoothie 2
Number of subjects: 10
Study 28736201 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain text message reminders
Number of subjects: 295
Study 28736201 — intervention group
Group type: COMPARATOR
Intervention: Educational text message reminders
Number of subjects: 295
Study 25994603 — intervention group
Group type: EXPERIMENTAL
Intervention: barnidipine+losartan
Number of subjects: 148
Study 25994603 — intervention group
Group type: COMPARATOR
Intervention: telmisartan+hydrochlorothiazide
Number of subjects: 148
Study 23869063 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adenosine, 140 μg·kg(‐1)·min(‐1), during 5 min
Number of subjects: 12
Study 23869063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21640424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention with structured patient education (DESMOND model)
Number of subjects: 189
Study 21640424 — intervention group
Group type: COMPARATOR
Intervention: Usual care by own health professional
Number of subjects: 189
Study 19957872 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea pallida and Echinacea simulata
Number of subjects: 0
Study 17425616 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 7.5 mg/ml plus isotonic sodium chloride solution
Number of subjects: 45
Study 17425616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg/ml plus 100 mg tramadol
Number of subjects: 45
Study 15040544 — intervention group
Group type: EXPERIMENTAL
Intervention: didanosine-stavudine-indinavir (IDV group)
Number of subjects: 60
Study 15040544 — intervention group
Group type: EXPERIMENTAL
Intervention: didanosine-stavudine-hydroxyurea (HU group)
Number of subjects: 60
Study 15040544 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study 11794558 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 68
Study 11794558 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment
Number of subjects: 68
Study 9713731 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% oxygen until the third postoperative morning (P = prolonged group)
Number of subjects: 24
Study 9713731 — intervention group
Group type: COMPARATOR
Intervention: 35% oxygen until the first postoperative morning (S = short group)
Number of subjects: 24